Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
82 hedge funds and large institutions have $211M invested in Avadel Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 19 closing their positions.
35% more capital invested
Capital invested by funds: $156M → $211M (+$55.2M)
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
4% more funds holding
Funds holding: 79 → 82 (+3)
0.81% more ownership
Funds ownership: 54.17% → 54.98% (+0.81%)
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
7% less call options, than puts
Call options by funds: $1.11M | Put options by funds: $1.2M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.65M |
| 2 |
GJL
Gendell Jeffrey L
|
+$3.54M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$2.72M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$2.72M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$4.16M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$2.54M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.95M |
| 4 |
Millennium Management
New York
|
-$1.66M |
| 5 |
Renaissance Technologies
New York
|
-$1.19M |
AVDL Hedge Fund Activity: Q4 2020 in Review
82 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2020, worth a combined $211M — up 35% from $156M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AVDL positions and 19 closed out — a net gain of 4 holders — while 21 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $3.65M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $4.16M sold.
- 82 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2020, up from 79 in Q3 2020.
- Funds reported $211M of Avadel Pharmaceuticals stock for Q4 2020, up 35% quarter-over-quarter.
- 23 funds opened new Avadel Pharmaceuticals positions in Q4 2020 and 19 closed out, a net change of +4 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2020 was BlackRock, an estimated $3.65M added.
- The largest Avadel Pharmaceuticals seller in Q4 2020 was Ghost Tree Capital, an estimated $4.16M sold.
Based on aggregated 13F filings for Q4 2020.